Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Novanta Inc. (NOVT): A Closer Look at This Precision Technology Supplier

Novanta Inc. (NOVT): A Closer Look at This Precision Technology Supplier

Key Takeaways

  • Novanta Inc. (NOVT) supplies precision photonics, vision, and motion-control components to medical and advanced industrial equipment makers worldwide.
  • The company works primarily with original equipment manufacturers (OEMs) rather than selling directly to end consumers.
  • Novanta reports results through two main segments: Automation Enabling Technologies and Medical Solutions.
  • Founded in 1968 as GSI Group, it rebranded to Novanta in 2016 and is based in Bedford, Massachusetts.
  • Its components appear in surgical robotics, laser manufacturing, DNA sequencing, and semiconductor tools, creating a diversified yet specialized revenue mix.

Company Background

Novanta Inc. develops and produces precision photonics, vision, and motion-control components and subsystems for healthcare and advanced industrial OEMs. The name itself highlights its emphasis on innovation and technical accuracy. I follow the company because it holds a unique spot in the supply chain, delivering the specialized parts that power medical devices, lab instruments, laser systems, and factory automation equipment from leading global manufacturers.

Business Model and Segments

Novanta dates back to 1968 and operated for years as GSI Group before the 2016 rebrand. Headquartered in Bedford, Massachusetts, it runs design and manufacturing sites across North America, Europe, and Asia with a team of about 3,000 people. The model focuses on mission-critical, engineered components built into customers’ products. These solutions often have long life cycles and strict performance standards, which helps create switching costs and lasting relationships. Sales occur through direct teams and distributors, and growth has come from a steady acquisition approach that brings in complementary technologies.

Results break down into two segments. The Automation Enabling Technologies segment covers laser beam steering, laser sources such as CO2 and ultrafast lasers, encoders, precision motors, motion control, robotic tooling, and air-bearing spindles. These support industrial processing, robotics, metrology, and certain medical laser uses. The Medical Solutions segment includes insufflators, endoscopic pumps, imaging and RFID solutions, advanced motion control, light engines, and integrated operating-room systems for minimally invasive procedures. The segments contribute fairly evenly to revenue, reflecting a balanced medical and industrial exposure. The company maintains a portfolio of brands including Cambridge Technology, Synrad, Laser Quantum, ARGES, Celera Motion, ATI Industrial Automation, JADAK, and Westwind.

Why Investors Follow NOVT

Novanta draws interest because it aligns with long-term trends in robotic surgery, lab automation, medical imaging, DNA sequencing, and precision manufacturing. As customers adopt more advanced equipment, demand for the components it supplies tends to rise in tandem. Competitive strengths include deep engineering know-how, a solid patent portfolio, and long design ties with major OEMs. Components are often customized and validated over years, which makes them hard to displace. The company has also shown consistent success with acquisitions that expand its offerings. A large share of sales comes from outside the United States. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Potential Risks

Novanta faces typical risks for a precision supplier. Demand can fluctuate with customers’ capital-spending cycles, which are sensitive to broader economic conditions. Customer concentration matters, as a handful of large OEMs can account for a notable portion of revenue, so losing one could have a sizable effect. Acquisitions bring integration and goodwill considerations, and related costs can affect short-term results. The company competes in fast-moving markets that require ongoing innovation, and its international operations expose it to currency swings, trade shifts, and regional volatility. Without a dividend, returns rely mainly on share-price growth.

Leveraging AI for Deeper Analysis

When evaluating names like NOVT, I often turn to Tickeron’s AI Screener to compare technical indicators, fundamentals, and industry patterns. It helps surface ideas that align with specific strategies and keeps the research process efficient without replacing my own judgment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NOVT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


NOVT sees MACD Histogram crosses below signal line

NOVT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 55 instances where the indicator turned negative. In 42 of the 55 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NOVT as a result. In 69 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

NOVT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NOVT crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 68%.

The 50-day moving average for NOVT moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NOVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +10.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where NOVT advanced for three days, in 195 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

NOVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. NOVT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.162) is normal, around the industry mean (1.448). P/E Ratio (85.000) is within average values for comparable stocks, (5.350). NOVT's Projected Growth (PEG Ratio) (23.270) is slightly higher than the industry average of (5.470). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (5.043) is also within normal values, averaging (32.028).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NOVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Industry description

This industry manufactures electronic products used in various critical and sophisticated technologies, including laser-based systems, circuit and continuity testers, electro-optical measuring instruments and high-speed precision weighing and inspection equipment. Some major companies operating in this business are Canon Inc., Keysight Technologies Inc., and Fortive Corp.

Market Cap

The average market capitalization across the Electronic Equipment/Instruments Industry is 7.99B. The market cap for tickers in the group ranges from 12.56K to 120.89B. KYCCF holds the highest valuation in this group at 120.89B. The lowest valued company is FLXT at 12.56K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Equipment/Instruments Industry was 5%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -13%. FCUV experienced the highest price growth at 130%, while ARAI experienced the biggest fall at -51%.

Volume

The average weekly volume growth across all stocks in the Electronic Equipment/Instruments Industry was 87%. For the same stocks of the Industry, the average monthly volume growth was 232% and the average quarterly volume growth was 107%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 50
Price Growth Rating: 61
SMR Rating: 78
Profit Risk Rating: 81
Seasonality Score: 6 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of manufactures and sells precision photonic and motion control components

Industry ElectronicEquipmentInstruments

Industry
Electronic Equipment Or Instruments
Address
125 Middlesex Turnpike
Phone
+1 781 266-5700
Employees
3000
Web
https://www.novanta.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.
Lead catalyst: Chemomab has secured alignment with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a single Phase 3 registration trial for nebokitug in primary sclerosing cholangitis (PSC), a rare liver disease with no approved disease-modifying therapy. Strategic pivot: A planned merger with Scipher Medicine is expected to close by year-end 2026, extending nebokitug into an AI-powered, precision-medicine Phase 2 trial in rheumatoid arthritis (RA).